Haplotype analysis of p53 polymorphisms: Arg72Pro, Ins16bp and G13964C in Tunisian patients with familial or sporadic breast cancer

Cancer Epidemiology

Volumn 34, Issue 2, 2010, Pages 184-188

  Trifa, Fatma ^a   Karray Chouayekh, Sondes ^a   Mabrouk, Imed ^a   Baccouche, Sami ^a   Khabir, Abdelmajid ^b   Sellami Boudawara, Tahia ^b   Gargouri, Ali ^a   Mokdad Gargouri, Raja ^a  

^a CENTRE DE BIOTECHNOLOGIE DE SFAX   (Tunisia)

^b HABIB BOURGUIBA HOSPITAL   (Tunisia)

Author keywords

Breast cancer; Haplotypes; p53; Polymorphisms

Indexed keywords

ARGININE; CYTOSINE; GENOMIC DNA; GUANOSINE; PROLINE; PROTEIN P53; DNA; TP53 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER RISK; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; DNA POLYMORPHISM; FAMILIAL CANCER; FEMALE; GENE FREQUENCY; GENOTYPE; HAPLOTYPE; HUMAN; HUMAN CELL; INTRON; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL ANALYSIS; TUNISIA; BLOOD; BREAST TUMOR; CASE CONTROL STUDY; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED; TUMOR SUPPRESSOR GENE; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CASE-CONTROL STUDIES; DNA, NEOPLASM; FEMALE; GENES, P53; GENETIC PREDISPOSITION TO DISEASE; HAPLOTYPES; HUMANS; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; TUMOR SUPPRESSOR PROTEIN P53; TUNISIA; YOUNG ADULT;

EID: 77950371644     PISSN: 18777821     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canep.2010.02.007     Document Type: Article

References (48)

1. Hollstein M., Sidransky D., Vogelstein B., and Harris C.C. p53 mutations in human cancers. Science 253 (1991) 49-53
2. Hainaut P., and Hollstein M. p53 and human cancer: the first thousand mutations. Adv Cancer Res 77 (2000) 81-137
3. Olivier M., Eclcs R., Hollstein M., Khan M.A., Harris C.C., and Hainaut P. The IARC TP53 database: new online mutation analysis and recommendations to users. Hum Mutat 19 (2002) 607-614
4. Dumont P., Leu J.I., Della Pietra A.C., George D.L., and Murphy M. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 3 (2003) 357-365
5. Gemignani F., Moreno V., Landi S., Moullan N., Chabrier A., Gutierrez-Enriquez S., et al. A TP53 polymorphism is associated with increased risk of colorectal cancer and with reduced levels of TP53 mRNA. Oncogene 23 (2004) 1954-1956
6. Wu X., Zhao H., Amos C.I., Shete S., Makan N., Hong W.K., et al. p53 genotypes and haplotypes associated with lung cancer susceptibility and ethnicity. J Natl Cancer Inst 94 (2002) 681-690
7. Lehman T.A., Haffty B.G., Carbone C.J., Bishop L.R., Gumbs A.A., Krishnan S., et al. Elevated frequency and functional activity of a specific germ-line p53 intron mutation in familial breast cancer. Cancer Res 60 (2000) 1062-1069
8. Costa S., Pinto D., Pereira D., Rodrigues H., Cameselle-Teijeiro J., Medeiros R., et al. Importance of TP53 codon 72 and intron 3 duplication 16bp polymorphisms in prediction of susceptibility on breast cancer. BMC Cancer 8 (2008) 32
9. Runnebaum I.B., Tong X.W., Konig R., Zhao H., Korner K., Atkinson E.N., et al. p53-based blood test for p53PIN3 and risk for sporadic ovarian cancer. Lancet 345 (1995) 994
10. Khaliq S., Hameed A., Khaliq T., Ayub Q., Qamar R., Mohyuddin A., et al. P53 mutations, polymorphisms, and haplotypes in Pakistani ethnic groups and breast cancer patients. Genet Test 4 (2000) 23-29
11. Osorio A., Pollán M., Pita G., Schmutzler R.K., Versmold B., Engel C., et al. An evaluation of the polymorphisms Ins16bp and Arg72Pro in p53 as breast cancer risk modifiers in BRCA1 and BRCA2 mutation carriers. Br J Cancer 99 (2008) 974-977
12. Matlashewski G.J., Tuck S., Pim D., Lamb P., Schneider J., and Crawford L.V. Primary structure polymorphism at amino acid residue 72 of human p53. Mol Cell Biol 7 (1987) 961-963
13. Buyru N., Tigli H., and Dalay N. p53 codon 72 polymorphism in breast cancer. Oncol Rep 10 (2003) 711-714
14. Jin X., Wu X., Roth J.A., Amos C.I., King T.M., Branch C., et al. Higher lung cancer risk for younger African-Americans with the Pro/Pro p53 genotype. Carcinogenesis 16 (1995) 2205-2208
15. Thomas M., Kalita A., Labrecque S., Pim D., Banks L., and Matlashewski G. Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol 19 (1999) 1092-1100
16. Sullivan A., Syed N., Gasco M., Bergamaschi D., Trigiante G., Attard M., et al. Polymorphism in wild-type p53 modulates response to chemotherapy in vitro and in vivo. Oncogene 23 (2004) 3328-3337
17. Pim D., and Banks L. p53 polymorphic variants at codon 72 exerts different effects on cell cycle progression. Int J Cancer 108 (2004) 196-199
18. Zhou Y., Li N., Zhuang W., Liu G.J., Wu T.X., Yao X., et al. P53 codon 72 polymorphism and gastric cancer: a meta-analysis of the literature. Int J Cancer 121 (2007) 1481-1486
19. Klug S.J., Ressing M., Koenig J., Abba M.C., Agorastos T., Brenna S.M.F., et al. TP53 codon 72 polymorphism and cervical cancer: a pooled analysis of individual data from 49 studies. Lancet Oncol 10 (2009) 772-784
20. Zhang Z., Wang M., Wu D., Wang M., Tong N., Tian Y., et al. P53 codon 72 polymorphism contributes to breast cancer risk: a meta-analysis based on 39 case-control studies. Breast Cancer Res Treat (2009)
21. Dai S., Mao C., Jiang L., Wang G., and Cheng H. P53 polymorphism and lung cancer susceptibility: a pooled analysis of 32 case-control studies. Hum Genet 125 (2009) 633-638
22. Buller R.E., Skilling J.S., Kaliszewski S., Niemann T., and Anderson B. Absence of significant of germ line p53 mutations in ovarian cancer patients. Gynecol Oncol 58 (1995) 368-374
23. Varley J.M., McGown G., Thorncraft M., Kelsey A.M., and Birch J.M. Significance of intron 6 sequence variations in the TP53 gene in Li- Fraumeni syndrome. Cancer Genet Cytogenet 29 (2001) 85-87
24. Fiszer-Maliszewska L., Kazanowska B., Kusnierczyk P., Manczak M., Nicpieklo W., Pachron-Zeman B., et al. Is p53 intronic variant G13964C associated with predisposition to cancer?. J Appl Genet 44 (2003) 547-552
25. Goldman R., and Shields P.G. Molecular epidemiology of breast cancer. In Vivo 12 (1998) 43-48
26. Stratton MR, Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Breast Cancer Linkage Consortium. Lancet 1997;349:1505-10.
27. Miller S.A., Dykes D.D., and Polesky H.F. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acid Res 16 (1988) 1215
28. Sham P.C., and Curtis D. Monte Carlo tests for associations between disease and alleles at highly polymorphic loci. Ann Hum Genet 59 (1995) 97-105
29. Buyru N., Altinisik J., Demokan S., and Dalay N. p53 genotypes and haplotypes associated with risk of breast cancer. Cancer Detect Prev 31 (2007) 207-213
30. Sjalander A., Birgander R., Hallmans G., Cajander S., Lenner P., Athlin L., et al. p53 polymorphisms and haplotypes in breast cancer. Carcinogenesis 17 (1996) 1313-1316
31. De Vecchi G., Verderio P., Pizzamiglio S., Manoukian S., Bernard L., Pensotti V., et al. The p53 Arg72Pro and Ins16bp polymorphisms and their haplotypes are not associated with breast cancer risk in BRCA-mutation negative familial cases. Cancer Detect Prev 32 (2008) 140-143
32. Suspitsin E.N., Buslov K.G., Grigoriev M.Y., Ishutkina J.G., Ulibina J.M., Gorodinskaya V.M., et al. Evidence against involvement of p53 polymorphism in breast cancer predisposition. Int J Cancer 103 (2003) 431-433
33. Weston A., Pan C.F., Ksieski H.B., Wallenstein S., Berkowitz G.S., Tartter P.I., et al. p53 haplotype determination in breast cancer. Cancer Epidemiol Biomarkers Prev 6 (1997) 105-112
34. Wang-Gohrke S., Becher H., Kreienberg R., Runnebaum I.B., and Chang- Claude J. Intron 3 16bp duplication polymorphism of p53 is associated with an increased risk for breast cancer by the age of 50 years. Pharmacogenetics 12 (2002) 269-272
35. Papadakis E., Soulitzis N., and Spandidos D.A. Association of p53 codon 72 polymorphism with advanced lung cancer: the Arg allele is preferentially retained in tumours arising in Arg/Pro germline heterozygotes. Br J Cancer 87 (2002) 1013-1018
36. Sjalander A., Birgander R., Athlin L., Stenling R., Rutegard J., Beckman L., et al. P53 germline haplotypes associated with increased risk for colorectal cancer. Carcinogenesis 16 (1995) 1461-1464
37. Lancester J.M., Brownlee H.A., Wiseman R.W., and Taylor J. p53 poymorphism in ovarian and bladder cancer. Lancet 346 (1995) 182
38. Papadakis E.N., Dokianakis D.N., and Spandidos D.A. p53 Codon 72 polymorphism as a risk factor in the development of breast cancer. Mol Cell Biol Res Commun 3 (2000) 389-392
39. Damin A.P., Frazzon A.P., Damin D.C., Roehe A., Hermes V., Zettler C., et al. Evidence for an association of TP53 codon 72 polymorphism with breast cancer risk. Cancer Detect Prev 30 (2006) 523-529
40. Hadhri-Guiga B., Toumi N., Khabir A., Sellami-Boudawara T., Ghorbel A., Daoud J., et al. Proline homozygosity in codon 72 of TP53 is a factor of susceptibility to nasopharyngeal carcinoma in Tunisia. Cancer Genet Cytogenet 178 (2007) 89-93
41. Granja F., Morari J., Morari E.C., Correa L.A., Assumpcao L.V., and Ward L.S. Proline homozygosity in codon 72 of p53 is a factor of susceptibility for thyroid cancer. Cancer Lett 210 (2004) 151-157
42. Singh V., Rastogi N., Mathur N., Singh K., and Singh M.P. Association of polymorphism in MDM-2 and p53 genes with breast cancer risk in Indian women. Ann Epidemiol 18 (2008) 48-57
43. Baccouche S., Mabrouk I., Said S., Mosbah A., Jlidi R., and Gargouri A. A more accurate detection of codon 72 polymorphism and LOH of the TP53 gene. Cancer Lett 189 (2003) 91-96
44. Khadang B., Fattahi M.J., Talei A., Dehaghani A.S., and Ghaderi A. Polymorphism of TP53 codon 72 showed no association with breast cancer in Iranian women. Cancer Genet Cytogenet 173 (2007) 38-42
45. Marsh A., Spurdle A.B., Turner B.C., Fereday S., Thorne H., Pupo G.M., et al. The intronic G13964C variant in p53 is not a high risk mutation in familial breast cancer in Australia. Breast Cancer Res 3 (2001) 346-349
46. Osorio A., Martinez-Delgado B., Pollan M., Cuadros M., Urioste M., Torrenteras C., et al. A haplotype containing the p53 polymorphisms Ins16bp and Arg72Pro modifies cancer risk in BRCA2 mutation carriers. Hum Mutat 27 (2006) 242-248
47. Cavallone L., Arcand S.L., Maugard C., Ghadirian P., Mes-Masson A.M., Provencher D., et al. Haplotype analysis of TP53 polymorphisms, Arg72Pro and Ins16, in BRCA1 and BRCA2 mutation carriers of French Canadian descent. BMC Cancer 8 (2008) 1-9
48. Gallì P., Cadoni G., Volante M., De Feo E., Amore R., Giorgio A., et al. A case-control study on the combined effects of p53 and p73 polymorphisms on head and neck cancer risk in an Italian population. BMC Cancer 9 (2009) 1-9